Pharmaceutical News and Articles
Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Including pharmaceutical industry news, new drug approvals, applications and clinical trial results.
Pharma News
EXTON, Pa.--(BUSINESS WIRE)--Jul 3, 2008 - Adolor Corporation
(Nasdaq: ADLR) today issued an update on the Entereg(R) (alvimopan)
Program for chronic opioid bowel dysfunction (OBD), under
development in collaboration with GlaxoSmithKline (NYSE:...
BASINGSTOKE, England and CAMBRIDGE Massachusetts, July 03, 2008
/PRNewswire-FirstCall/ --
- Shire proposes acquisition of biotechnology company, Jerini AG for an
equity purchase price of EUR328 million adding hereditary angioedema
...
Support to Focus on Academic Medical Centers, Hospitals,
Associations and Medical Societies
Move Eliminates Direct Support for Commercial CME Providers
NEW YORK--(BUSINESS WIRE)--Pfizer today announced changes in the
way it supports continuing...
PARIS AND NEW YORK, July 2, 2008 – Publicis
Groupe [Euronext Paris : FR0000130577] announced today that it
has acquired Kekst and Company, Incorporated, a leading strategic
and financial public relations firm based in New York. Kekst...
New Drug Approvals
LIBERTY CORNER, N.J., July 03, 2008 /PRNewswire/ -- On June 27,
2008 GeneraMedix Inc. received approval from the U.S. Food and Drug
Administration (FDA) for its Epoprostenol for Injection 1.5 mg New
Drug Application (NDA).
Epoprostenol for...
Xience V, Only Drug Eluting Stent to Demonstrate Superiority Over
Market-Leading Stent in Clinical Trials, Now Available in United
States for Treatment of Coronary Artery Disease
ABBOTT PARK, Ill., July 02, 2008 /PRNewswire-FirstCall/ --
Abbott...
ROCKVILLE, Md., July 1, 2008-The U.S. Food and Drug
Administration today approved the first generic versions of
Risperdal (risperidone) tablets. Risperdal is an antipsychotic drug
used for the treatment of schizophrenia, bipolar disorder,...
WOODCLIFF LAKE, N.J., June 30, 2008 /PRNewswire/ -- Eisai
Corporation of North America, a wholly-owned subsidiary of
Tokyo-based Eisai Co., Ltd., announced today that the Food and Drug
Administration (FDA) has approved Aciphex (rabeprazole...
HERZLIYA, Israel & MORRIS PLAINS, N.J.--(BUSINESS WIRE)--Jun
30, 2008 - The U.S. Food and Drug Administration ("FDA") today
announced the approval of Evolence for the correction of
moderate to deep facial wrinkles and folds, such as...
Metvixia and Aktilite CL128 approved by FDA
OSLO, Norway, 27 June 2008 - Photocure ASA announces today
that Metvixia in combination with Aktilite CL128, the LED
based narrow band (630 nm) red light technology device has been
approved by US Food...
New Drug Applications
BASKING RIDGE, N.J., July 1, 2008 - VioQuest Pharmaceuticals
(OTCBB: VOQP) today announced the submission of a 510(k)
application to the United States Food and Drug Administration
(FDA). The application seeks marketing clearance for Xyfid...
MELBOURNE, Australia & MENLO PARK, Calif.-- ChemGenex
Pharmaceuticals announced today that it has
submitted the non-clinical section of the rolling submission of a
New Drug Application (NDA) for omacetaxine mepesuccinate (formerly
known as...
BRIDGEWATER, NJ--(Marketwire - June 30, 2008) - Alpharma Inc.,
a global specialty pharmaceutical company, today announced that it
has resubmitted its New Drug Application ("NDA") for Embeda
(morphine sulfate extended-release with sequestered...
LEXINGTON, Mass.--(BUSINESS WIRE)--Jul 1, 2008 - EPIX
Pharmaceuticals, Inc., a biopharmaceutical company
focused on discovering and developing novel therapeutics through
the use of its proprietary and highly efficient in silico drug
discovery...
WATERTOWN, Mass.--(BUSINESS WIRE)--Jun 30, 2008 - Acusphere, Inc. announced today that the New Drug Application (NDA)
for approval to market its lead product candidate, Imagify
(Perflubutane Polymer Microspheres for Injectable Suspension),...
Company Announces Revised Operating Plan to Respond to Nebido Delay
LEXINGTON, Mass., June 30, 2008 /PRNewswire-FirstCall/ --
Indevus Pharmaceuticals, Inc. today announced that it has received
an approvable letter from the U.S. Food and Drug...
LONDON and PHILADELPHIA, June 30, 2008 /PRNewswire-FirstCall/ --
GlaxoSmithKline today provided the following update regarding its
application to the U.S. Food and Drug Administration (FDA) for
approval of Cervarix, its vaccine to prevent...
Advexin Targets Gene Defect Common to Majority of Tumors
AUSTIN, Texas & DUBLIN, Ireland--(BUSINESS WIRE)--June 30,
2008--Introgen Therapeutics, Inc. submitted a
Biologics License Application (BLA) to the U.S. Food and Drug
Administration (FDA)...
KENILWORTH and WHITEHOUSE STATION, N.J., June 27, 2008
/PRNewswire-FirstCall/ -- Schering-Plough Corp. and Merck &
Co., Inc. announce the withdrawal of the New Drug Application (NDA)
for the loratadine/montelukast combination tablet.
The...
Extensive Clinical Development Program Investigating Golimumab in
the Treatment of These Diseases Serves as Basis for the Application
HORSHAM, Pa., June 27, 2008 /PRNewswire/ -- Centocor, Inc.
announced today that a Biologics License Application...
PRINCETON, N.J., June 25, 2008 /PRNewswire/ -- The U.S. Food and
Drug Administration (FDA) Advisory Committee on Cardiovascular and
Renal Drugs voted to recommend the approval of tolvaptan, Otsuka
Pharmaceutical Development & Commercialization,...
Companies confirm the start of TRILOGY ACS clinical trial to study
Prasugrel against Clopidogrel in medically managed ACS patients
TOKYO and INDIANAPOLIS, June 23, 2008 /PRNewswire-FirstCall/ --
Daiichi Sankyo Company, Limited, and Eli Lilly and...
Clinical Trials
SAN FRANCISCO, July 03, 2008 /PRNewswire-FirstCall/ --
Medivation, Inc. today announced that it will hold a teleconference
at 5:00 p.m. EDT on Monday, July 7, to discuss top-line results
from its randomized, double-blind, placebo-controlled Phase...
MUNICH, Germany, July 3,2008- Munich-based biopharmaceutical
company WILEX AG (ISIN DE0006614720 / Frankfurt Stock Exchange /
Prime Standard) today announced that it has successfully completed
patient recruitment in the Phase III ARISER trial with...
HOUSTON, July 2, 2008 – Thyroid cancer that has
spread to distant sites has a poor prognosis, but an experimental
drug that inhibits tumor blood vessel formation can slow disease
progression in some patients, a research team led by...
HAMBURG, Germany, July 3, 2008 -Evotec AG (Frankfurt Stock
Exchange: EVT; NASDAQ: EVTC) announced today top-line results of a
double-blind, 4-week Phase Ib study with EVT 101, an orally active
NR2B-subtype selective antagonist of NMDA receptors...
